Literature DB >> 7036224

Prostacyclin is not a circulating hormone.

E Christ-Hazelhof, D H Nugteren.   

Abstract

Gas chromatography with electron-capture detection of the extensively purified pentafluorobenzyl derivative of 6-oxo-PGF1 alpha was used to determine prostacyclin in blood. Neither human peripheral plasma or whole blood, nor blood drawn directly from the human heart (blood from the right and left atrium which is comparable to pulmonary artery and vein blood), contained any detectable prostacyclin (less than 20 pg/ml). Even hyperventilation did not result in detectable PGI2-formation. During intravenous infusion of PGI2 into one arm, large amounts were found in blood drawn from the other arm. Increased levels were also found during severe infection and in endotoxin shock. These results lend no support to theories based on the concept that prostacyclin is a circulating hormone under normal conditions.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7036224     DOI: 10.1016/0090-6980(81)90213-6

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  19 in total

Review 1.  The eicosanoids and their biochemical mechanisms of action.

Authors:  W L Smith
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

2.  Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  The effect of nifedipine, nimodipine and nisoldipine on agonist- and trauma-stimulated vascular prostacyclin synthesis in vitro.

Authors:  J Y Jeremy; D P Mikhailidis; P Dandona
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

5.  Endogenous dilator prostaglandins in congenital heart disease.

Authors:  C Hammerman; M J Aramburo; K C Bui
Journal:  Pediatr Cardiol       Date:  1987       Impact factor: 1.655

6.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Authors:  P Patrignani; P Filabozzi; C Patrono
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

7.  Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Authors:  H Pickles; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

8.  Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation.

Authors:  R Brandt; A Dembińska-Kieć; R Korbut; R J Gryglewski; J Nowak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-01       Impact factor: 3.000

9.  Effects of acute pressure overload on prostacyclin release and myocardial blood flow in canine hearts: inhibition of prostacyclin synthesis with 15-hydroperoxy-eicosatetraenoic acid.

Authors:  M Imaizumi; Y Ito; T Ito; K Ogawa; T Satake
Journal:  Heart Vessels       Date:  1987       Impact factor: 2.037

10.  Modification of endotoxin-induced haemodynamic and haematological changes in the rabbit by methylprednisolone, F(ab')2 fragments and rosmarinic acid.

Authors:  H Bult; A G Herman; M Rampart
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.